Enveric Biosciences (ENVB) Depreciation & Amortization (CF) (2015 - 2026)
Enveric Biosciences (ENVB) posted Depreciation & Amortization (CF) of $37240.0 for Q1 2026, down 5.68% sequentially from $39483.0 in Q4 2025, and down 4.12% YoY from $38842.0 in Q1 2025.
Enveric Biosciences (ENVB) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Enveric Biosciences has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $37240.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 4.12% year-over-year to $37240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157074.0 (down 4.43% YoY) and the FY2025 annual result came in at $158676.0, down 5.96% from the prior year.
- Depreciation & Amortization (CF) retreated to $37240.0 in Q1 2026 per ENVB's latest filing, from $39483.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $44458.0 in Q3 2022 and troughed at $27077.0 in Q1 2022.
- A 5-year average of $41120.2 and a median of $42591.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 300.27% in 2022, down 74.4% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $44310.0 in 2022, then retreated by 4.1% to $42494.0 in 2023, then decreased by 5.16% to $40301.0 in 2024, then decreased by 2.03% to $39483.0 in 2025, then retreated by 5.68% to $37240.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $37240.0, $39483.0, and $40369.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,240.00 |
| Mar 31, 2026 | 37,240.00 |
| Dec 31, 2025 | 39,483.00 |
| Dec 31, 2025 | 39,483.00 |
| Sep 30, 2025 | 40,369.00 |
| Sep 30, 2025 | 40,369.00 |
| Jun 30, 2025 | 39,982.00 |
| Jun 30, 2025 | 39,982.00 |
| Mar 31, 2025 | 38,842.00 |
| Mar 31, 2025 | 38,842.00 |
| Dec 31, 2024 | 40,301.00 |
| Dec 31, 2024 | 40,301.00 |
| Sep 30, 2024 | 42,626.00 |
| Sep 30, 2024 | 42,626.00 |
| Jun 30, 2024 | 42,591.00 |
| Jun 30, 2024 | 42,591.00 |
| Mar 31, 2024 | 43,221.00 |
| Mar 31, 2024 | 43,221.00 |
| Dec 31, 2023 | 42,494.00 |
| Dec 31, 2023 | 42,494.00 |